Explore the potential of gene therapy as a groundbreaking approach to curing diseases, beyond traditional pharmacological ...

Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Stock Code: 2563.HK), today announced that the first patient has been dosed for one of its key ...

Bold Steps New Hampshire is proud to announce its continued growth with the addition of a new facility in Concord, expanding its ability to serve the Medicaid population and increase access to ...

Gene silencing has become a powerful therapeutic approach that has transformed the treatment paradigm for certain conditions, especially a handful of poorly treated rare diseases. Rather than directly ...

Even more exciting, they found that treating the liver—not the brain—can reverse these problems. Their study, published in ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with ...

CRISPR became big in 2025, bringing advances for serious Indian health risks, which will continue in the coming year ...

Detailed price information for Wave Life Sci Ord Sh (WVE-Q) from The Globe and Mail including charting and trades.

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% ...